San Diego-centered Viking Therapeutics marked by itself as a serious competitor from the weight loss drug sector in February just after revealing promising information from a mid-phase demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when given for a weekly injection As well as in March the compa